ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
release including its anticipated revenue and earnings per share
for the fiscal year ended December 31, 2016. A copy of the press
release is furnished as Exhibit 99.1 to this Form 8-K.
Accounting Principles, or GAAP, and non-GAAP financial measures.
The non-GAAP financial measures exclude the impact of share-based
compensation expense, fair value adjustment of inventory acquired,
amortization of purchased intangible assets, changes in fair value
of contingent consideration, acquisition-related costs,
restructuring expenses, upfront and milestone payments related to
licenses and collaborations, and adjustments to income tax expense.
Reconciliations between non-GAAP and GAAP financial measures are
included in the press release set forth as Exhibit 99.1 furnished
to this Form 8-K. Alexion’s management utilizes non-GAAP financial
information to provide a useful measure of comparative operating
performance of Alexion. The non-GAAP financial measures are
supplemental to and not a substitute for, measures of financial
performance prepared in accordance with GAAP.
|
|
|
|
99.1
|
Press Release issued by Alexion Pharmaceuticals, Inc. on
January 4, 2017. |
About ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders. ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Recent Trading Information
ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) closed its last trading session up +12.04 at 139.15 with 3,158,400 shares trading hands.
